Last reviewed · How we verify
NCT03297164
Incidence Rate of Heart Failure After Acute Myocardial Infarction With Optimal Treatment
trial in Acute Myocardial Infarction in 12,043 participants. Completed in 30 June 2021.
4 December 2020
Quick facts
| Lead sponsor | Harbin Medical University |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 12,043 |
| Start date | 21 December 2017 |
| Primary completion | 4 December 2020 |
| Estimated completion | 30 June 2021 |
| Sites | 19 locations across China |
Conditions studied
- Acute Myocardial Infarction — all drugs for Acute Myocardial Infarction →
- Heart Failure — all drugs for Heart Failure →
Sponsor
Harbin Medical University
Who can join
18 and older, any sex, with Acute Myocardial Infarction or Heart Failure. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The main purpose of this study is to build a multi-center, prospective and regionally representative acute myocardial infarction(AMI) cohort，and build a study platform for heart failure caused by AMI; To explore the 1 year incidence rate of heart failure after AMI given the optimized treatment and the treatment model affecting the incidence rate of heart failure, and finally to reduce the incidence rate of heart failure by 5%.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
-
Prevalence and prognostic significance of DNMT3A- and TET2- clonal haematopoiesis-driver mutations in patients presenting with ST-segment elevation myocardial infarction.
Wang S, Hu S, Luo X, Bao X, et al · · 2022 · cited 66× · PMID 35339897 · DOI 10.1016/j.ebiom.2022.103964 -
Clinical Characteristics and Prognosis of MINOCA Caused by Atherosclerotic and Nonatherosclerotic Mechanisms Assessed by OCT.
Zeng M, Zhao C, Bao X, Liu M, et al · · 2023 · cited 44× · PMID 36648054 · DOI 10.1016/j.jcmg.2022.10.023 -
Higher Peripheral Thyroid Sensitivity Is Linked to a Lower Risk of Heart Failure After Acute Myocardial Infarction.
Lang X, Zhao B, Fang S, Li L, et al · · 2023 · cited 9× · PMID 37104944 · DOI 10.1210/clinem/dgad240 -
A Novel Risk Score to Predict In-Hospital Mortality in Patients With Acute Myocardial Infarction: Results From a Prospective Observational Cohort.
Li L, Zhang X, Wang Y, Yu X, et al · · 2022 · cited 3× · PMID 35463775 · DOI 10.3389/fcvm.2022.840485 -
Pseudo-targeted metabolic profile differences between emergency patients with type 1 and type 2 myocardial infarction diagnosed by optical coherence tomography.
Wang J, Li Z, Yang G, Fang C, et al · · 2024 · cited 1× · PMID 38185283 · DOI 10.1016/j.cca.2023.117745 -
Risk factors and assessment system for cardiogenic death and stroke in patients with premature acute myocardial infarction.
Hou X, Liu J, Zhang J, Wang X, et al · · 2026 · PMID 41500028 · DOI 10.1016/j.hrtlng.2025.102716 -
Circadian rhythm pattern of symptom onset in patients with ST-segment elevation myocardial infarction in the Chinese population.
Guo Y, Cui L, Li L, Wang Z, et al · · 2024 · PMID 39720211 · DOI 10.3389/fcvm.2024.1393390 -
Machine learning-based prediction of return to work within 12 months in acute myocardial infarction patients
Wu X, Wang S, Cui H, Zheng X, et al · · 2024 · DOI 10.21203/rs.3.rs-4619695/v1
Verify or expand the search:
- PubMed search for NCT03297164
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Acute Myocardial Infarction
Currently open trials in the same condition.
- NCT03951467 — Using an Intervention Adapted to the Health Literacy Level to Improve Adherence to Medical Recommendations · NA · recruiting
- NCT07536802 — Adenosine Pre-Medication in Primary Percutaneous Coronary Intervention: A Randomized Control Trial · Phase 4 · recruiting
- NCT06947135 — Stellate Ganglion Morphine Infiltration on Myocardial Ischemia-Reperfusion Injury · NA · recruiting
- NCT06515730 — Treatment With Apixaban Versus Warfarin in Patients With Left Ventricular Thrombus After Acute Myocardial Infarction · Phase 4 · recruiting
- NCT07522164 — Acute Myocardial Infarction Clinical Cohort · active not recruiting
Other Harbin Medical University trials
Trials by the same sponsor.
- NCT07471815 — Camrelizumab Plus Risedronate and Chemotherapy for Triple-Negative Breast Cancer: An Exploratory Clinical Study on Mecha · Phase 2 · active not recruiting
- NCT07187674 — The Neoadjuvant Treatment of Early High-risk Triple Negative Breast Cancer With HRD Positive With Iparomlimab and Tuvonr · NA · not yet recruiting
- NCT07161791 — Camrelizumab, Pirfenidone, and Chemotherapy in the Treatment of Advanced Triple-Negative Breast Cancer · Phase 1, PHASE2 · not yet recruiting
- NCT07033624 — Cardiovascular Risk Early Screening and Warning in Harbin : A Prospective Cohort Study · not yet recruiting
- NCT06947148 — The Impact of Comprehensive Post Hospital Management Based on DHI on Cardiac Function in Patients With HF · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03297164 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Harbin Medical University
- Last refreshed: 1 October 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03297164.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing